Cases & Deals

  • Home
  • Practices
  • Boehringer Ingelheim and Epizyme enter into global collaboration to develop novel epigenetic oncology therapies

Share

Boehringer Ingelheim and Epizyme enter into global collaboration to develop novel epigenetic oncology therapies

April 2019

Client(s) Boehringer Ingelheim GmbH

Jones Day represents Boehringer Ingelheim GmbH and Epizyme, Inc. in the establishment of a global patent portfolio related to small molecules to target enzymes within the helicase and histone acetyltransferase ("HAT") families.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.